Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

This results in an increase in tumor cell PSA expression followed by induction of apoptosis, which releases PSA into circulation. As tumor cell death occurs, the PSA is expected to decline or stabilize.

"Based on the encouraging responses and the tolerability profile we have seen in these end-stage patients, we are dose-escalating to 200 mg per day," commented Dr. Montgomery. "As we track time to progression through further treatment cycles, we expect that PSA levels will remain stable or continue to decline, consistent with the unique mechanism of this drug, which is distinct from other compounds in later-stage development for CRPC."

Howard Scher, M.D., Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering and Principal Investigator of the PCCTC, added: "These data provide initial evidence of activity in late-stage prostate cancer. The next step will be to expand the subject eligibility criteria to include earlier-stage, chemotherapy-naive patients in a controlled Phase II trial."

APOPTONE Clinical Trial Design

The study is an open-label study with the primary objective of assessing safety, tolerance, PK and activity of Apoptone in men with CRPC and an ECOG PS of <2 who failed at least one taxane-containing chemotherapy regimen and either radiographically or biochemically progressed. Patient cohorts are defined by oral twice-daily doses of 10 mg, 20 mg, 30 mg, 50 mg, 100 mg or higher (MTD has not yet been reached). Subjects are treated on 28-day cycles until toxicity or disease progression; CT and bone scans are obtained every two cycles to assess progression.

About Prostate Cancer

Over one million men in the United States have prostate cancer; approximately 90,000 of these patients have late-stage prostate cancer, resulting in approximately 28,000 deaths each year. There are currently no approved treat
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Calif. (PRWEB) , ... July 02, 2015 , ... Sleepless ... improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound ... Luzi's voice command technology makes it effortless to use, while the integration of the ...
(Date:7/1/2015)... ... , ... It is now possible to separate two common disorders: post-traumatic stress ... (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and University ... believed to be the largest brain imaging study ever, will be published on July ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... with Georgetown experts to address biotechnology, science, policy and ethical ... WASHINGTON ... of Health and the Food and Drug Administration outlined a "path ... treatments tailored to match a person,s genetic make-up.  Significant progress in this ...
... ... 2009 Corporate Sustainability Report. , ... Madison, WI USA (PRWEB) June 22, 2010 -- Promega reports significant reductions ... summarizes Promega goals and accomplishments to conserve natural resources, minimize environmental impacts and demonstrate ...
... of researchers from the University of Alberta and the National ... unsealed plastic solar cell, from mere hours to eight months. ... available plastic solar cell technology hit a wall because of ... A chemical coating on an electrode was unstable and migrated ...
Cached Biology Technology:Pebbles Along the 'Path' to Personalized Medicine 2Pebbles Along the 'Path' to Personalized Medicine 3Pebbles Along the 'Path' to Personalized Medicine 4Promega Releases 2009 Corporate Sustainability Report 2
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/24/2015)... , June 24, 2015 This report ... over the next six years. It contains an analysis ... industry, along with their impact from the short, medium, ... also discusses the industry, market, and technology trends that ... the need of concerned authorities to efficiently manage the ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... in the August 16th issue of Developmental Cell , ... that guarantees that new blood vessels form in the right ... for a long time that blood vessels branch to give ... our bodies this branching occurs with a reproducible pattern. However, ...
... Institutes have gained new insight into the delicate relationship between ... normal development of stem cells in the heart and may ... news, being announced in a paper published online today in ... the role of stem cells in embryonic heart development, and ...
... MD, August 15, 2011 The American Society of Addiction ... that addiction is a chronic brain disorder and not simply ... sex. This the first time ASAM has taken an official ... use. , When people see compulsive and damaging behaviors ...
Cached Biology News:Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3ASAM releases new definition of addiction 2ASAM releases new definition of addiction 3
... GeneTraffic is built to be a straightforward, ... provides visual and computational tools to allow ... analysis. , Data and Project Management ... MIAME (Minimum Information About a Microarray Experiment) ...
... are rigid macroporous hydrophilic media. The rigid ... moderate pressures, while the macroporous beads enhance ... matrix reduces nonspecific binding. Macro-Prep High Q ... with very high flow rates and resolution. ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
Biology Products: